Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.61 |
| ▸ | NADK | O95544 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191285 | 0.89 | AHCY (0.59) | AHCYNADKADORA3ADORA2AADORA2B | |
| SCHEMBL101380 | 0.89 | AHCY (0.62) | AHCYNADKADORA3ADORA2AADORA2B | |
| SCHEMBL6894498 | 0.87 | AHCY (0.59) | AHCYNADKADORA3ADORA2AADORA2B | |
| SCHEMBL18026180 | 0.87 | ADORA3 (0.63) | AHCYNADKADORA3ADORA2AADORA2B | |
| SCHEMBL21413842 | 0.87 | ADORA3 (0.63) | AHCYNADKADORA3ADORA2AADORA2B | |
| SCHEMBL21837298 | 0.87 | ADORA3 (0.63) | AHCYNADKADORA3ADORA2AADORA2B | |
| SCHEMBL800618 | 0.87 | ADORA3 (0.63) | AHCYNADKADORA3ADORA2AADORA2B | |
| SCHEMBL397800 | 0.86 | AHCY (0.68) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL31680251 | 0.86 | AHCY (0.68) | AHCYADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL22326785 | 0.85 | PRMT5 (0.64) | AHCYADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0693127-A1 | USE OF TOMATO E8-DERIVED PROMOTERS TO EXPRESS HETEROLOGOUS GENES, E.G. S-ADENOSYLMETHIONINE HYDROLASE, IN RIPENING FRUIT | EPITOPE, INC. (US) | 1996-01-24 | — | — | EP | claimed |
| WO-1994024294-A1 | USE OF TOMATO E8-DERIVED PROMOTERS TO EXPRESS HETEROLOGOUS GENES, E.G. S-ADENOSYLMETHIONINE HYDROLASE, IN RIPENING FRUIT | EPITOPE, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | AHCY 62/4885NADK 1514/4885ADORA3 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.